Jyong Biotech (NASDAQ:MENS) Trading 10.9% Higher – Still a Buy?

Shares of Jyong Biotech Ltd. (NASDAQ:MENS) shot up 10.9% during mid-day trading on Thursday . The company traded as high as $32.82 and last traded at $32.34. 13,327 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 283,789 shares. The stock had previously closed at $29.17.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Jyong Biotech presently has an average rating of “Sell”.

Jyong Biotech Stock Down 2.3%

The firm’s 50 day moving average price is $50.15.

Institutional Investors Weigh In On Jyong Biotech

A hedge fund recently bought a new stake in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new stake in shares of Jyong Biotech Ltd. (NASDAQ:MENS) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 1,698 shares of the company’s stock, valued at approximately $67,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.